[Skip to Content]
[Skip to Content Landing]
Comment & Response
January 2018

Hair Repigmentation With Anti–PD-1 and Anti–PD-L1 Immunotherapy: A Novel Hypothesis

Author Affiliations
  • 1Department of Hematology, CHU Rennes, Rennes, France
  • 2Gustave Roussy, Université Paris-Saclay, Département d’Innovation Thérapeutique et d’Essais Précoces, Villejuif, F-94805, France
  • 3INSERM U1015, Gustave Roussy, Villejuif, France
  • 4INSERM, U1236, Rennes, France
JAMA Dermatol. 2018;154(1):113. doi:10.1001/jamadermatol.2017.4421

To the Editor The article by Rivera et al1 is the first report of a previously undescribed side effect of checkpoint inhibitors: hair repigmentation (HR). In this significant case series of 14 patients, all patients received an anti–programmed cell death 1 (PD-1) and anti–programmed cell death 1 ligand 1 (PD-L1) antibody for the treatment of a lung cancer.

×